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Introduction
Cellular prion protein (PrPC) is a cell-surface, glycosyl-
phosphatidylinositol-anchored protein associated with several
physiological functions. PrPC is conserved among species and
is expressed in most tissues, especially in the central nervous
system and lymphoid tissues (Oesch et al., 1985). It has the
ability to bind copper (Brown et al., 1997), to protect against
oxidative stress (Brown and Besinger, 1998) and has been
shown to influence cell signaling mechanisms, neuronal
survival and differentiation (Chen, S. et al., 2003; Chiarini et
al., 2002; Lopes et al., 2005; Mouillet-Richard et al., 2000).
PrPC has also been shown to bind the laminin receptor
(Gauczynski et al., 2001; Hundt et al., 2001), to promote
neuritogenesis through its interaction with NCAM
(Santuccione et al., 2005; Schmitt-Ulms et al., 2001) and to
induce neurite maintenance and neuronal differentiation
through binding to the extracellular matrix (ECM) protein
laminin (Ln) (Graner et al., 2000a; Graner et al., 2000b).
ECM proteins are known to regulate neuronal differentiation
and axonal regeneration (Turney and Bridgman, 2005; Easley
et al., 2006; Tom et al., 2004). Vitronectin (Vn) is expressed
during development on embryonic day 10 (E10) in mice,
mainly in the central nervous system (Seiffert et al., 1995), and
has been shown to support proliferation and differentiation of
cultured neurons (Martinez-Morales et al., 1995). In dorsal root
ganglia (DRG) neurons, Vn-mediated axonal growth can be
inhibited by anti-Vn antibody (Isahara and Yamamoto, 1995).
Vn can also induce motor neuron differentiation, and anti-Vn
antibodies reduce the number of motor neurons generated in
chicken embryos (Martinez-Morales et al., 1997; Pons and
Marti, 2000).
The classical ECM receptors, integrins, can bind several
molecules and have been associated with ECM biological
functions. The integrin recognition sequence Arg-Gly-Asp
(RGD) is present in numerous ECM proteins including
collagen, Vn and Fibronectin (Fn). RGD peptide is
biologically active and able to substitute for ECM proteins in
a variety of situations (Hynes, 2002; Pierschbacher and
Ruoslahti, 1984).
Given that PrPC binds Ln, we hypothesized that PrPC might
act as a broad ECM ligand and tested whether PrPC binds the
ECM proteins Vn, Fn and type IV collagen. We also sought to
characterize the cellular events associated with any such
binding. We assessed the role of PrPC-ECM interaction in DRG
The physiological functions of the cellular prion protein,
PrPC, as a cell surface pleiotropic receptor are under
debate. We report that PrPC interacts with vitronectin but
not with fibronectin or collagen. The binding sites
mediating this PrPC-vitronectin interaction were mapped
to residues 105-119 of PrPC and the residues 307-320 of
vitronectin. The two proteins were co-localized in
embryonic dorsal root ganglia from wild-type mice.
Vitronectin addition to cultured dorsal root ganglia
induced axonal growth, which could be mimicked by
vitronectin peptide 307-320 and abrogated by anti-PrPC
antibodies. Full-length vitronectin, but not the vitronectin
peptide 307-320, induced axonal growth of dorsal root
neurons from two strains of PrPC-null mice. Functional
assays demonstrated that relative to wild-type cells, PrPC-
null dorsal root neurons were more responsive to the Arg-
Gly-Asp peptide (an integrin-binding site), and exhibited
greater v3 activity. Our findings indicate that PrPC plays
an important role in axonal growth, and this function may
be rescued in PrPC-knockout animals by integrin
compensatory mechanisms.
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axon outgrowth using primary cultures obtained from two
different PrPC-null mouse strains (ZrchI and Npu) and their
respective wild-type controls. The role of integrins in wild-type
and PrPC-null DRG axonal growth was also addressed and
integrin activity was evaluated using specific antibodies and in
functional assays using RGD peptide.
Results
PrPC-vitronectin interaction
The first evidence of the PrPC-Vn interaction was obtained with
an overlay experiment (Fig. 1a), in which we applied equal
mass aliquots of Vn, Ln, Fn, type IV collagen or bovine serum
albumin (BSA) onto a nitrocellulose membrane, which was
then incubated with 125I-His6-PrPC. The overlay showed that
PrPC binds Ln, as previously demonstrated (Graner et al.,
2000a), and also interacts with Vn (note that 10 g of Ln
represents 10 times fewer moles than the other proteins, owing
to its higher molecular mass of ~900 kDa). Conversely, PrPC
did not associate with Fn or type IV collagen. Binding assays
demonstrated that His6-PrPC binding to Vn is dose dependent
and saturable (Fig. 1b), with a Kd of 12 nM. His6-PrPC refolded
in the presence of copper (Zanata et al., 2002b) presented a
similar binding to Vn (data not shown). It is important to note
that the Vn used here was highly pure (see supplementary
material Fig. S1a), and recombinant PrPC analyzed by circular
dichroism spectra showed an -helix structure (Cordeiro et al.,
2004a; Cordeiro et al., 2004b).
PrPC interaction with 125I-Vn could be blocked dose-
dependently by competition with increasing concentrations of
unlabeled Vn, as well as by other PrPC ligands, such as stress-
inducible protein 1 (STI1) (Zanata et al., 2002b) and Ln (Graner
et al., 2000a; Graner et al., 2000b), but not by BSA (Fig. 1c).
Thus, only specific PrPC ligands can disrupt its binding
interactions. The peptide representing the specific PrPC binding
site in the STI1 molecule (STI1 peptide) (Chiarini et al., 2002;
Zanata et al., 2002b), but not that from Ln (Ln -1 peptide)
(Graner et al., 2000a), competed for the PrPC-Vn interaction
(Fig. 1d). These data suggest that STI1 and Vn share a binding
site in the PrPC molecule, whereas Ln must interact with another
PrPC domain. Other Vn ligands such as type I collagen, type IV
collagen and heparin were also tested for their ability to
compete with the PrPC-Vn interaction (supplementary material
Fig. S2b). Although they do not bind Vn in the same domain
as PrPC (supplementary material Fig. S2a), they are able to
disturb the PrPC-Vn interaction, probably by steric hindrance.
Characterization of the PrPC and Vn interacting domains
Of the twenty peptides from mouse PrPC covering the whole
protein sequence used to compete for PrPC-Vn binding, two of
them, corresponding to PrPC residues 103-122 and 113-132,
Journal of Cell Science 120 (11)
Fig. 1. Vn binds PrPC in vitro and other PrPC ligands can compete for this interaction. (a) Autoradiogram of overlay assay. Indicated amounts of
Ln, Fn, Vn, type IV collagen (Col) and BSA were adsorbed onto a membrane and allowed to bind to 125I-His6-PrPC. (b) PrPC-coated wells were
incubated with 125I-Vn at the indicated concentrations. Wells were washed and radioactivity was measured. Scatchard plot is shown as an inset.
The data represent mean ± s.d. (c) Competition assay in which 125I-Vn was incubated over PrPC-coated wells in the presence of increasing
concentrations of unlabeled Vn, STI1, Ln or BSA. Bound 125I-Vn differed from addition of 5 g unlabeled Vn (*P<0.001), addition of 10 g
unlabeled Vn or Ln (**P<0.001), or addition of 25 g unlabeled Vn, Ln or STI1 (***P<0.001) according to Tukey’s Test. (d) Competition
assay in which 125I-Vn was incubated over PrPC-coated wells in the presence of increasing concentrations of unlabeled STI1 peptide or Ln -1
peptide. The percentage of Vn binding was reduced in the presence of 20 or 40 M STI1 peptide (*P<0.02, Student’s t-test).
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1917PrPC-vitronectin induces axonal growth
effectively blocked (by ~80%) PrPC-Vn binding (Fig. 2a). This
implies that the amino acid sequence shared by both peptides
may represent the putative binding site for Vn in the PrPC
molecule. The binding and competition assays were always
performed with a freshly prepared peptide solution to avoid
possible neurotoxic aggregates (Chiarini et al., 2002; Ettaiche
et al., 2000). The lack of PrPC-Vn interaction blockade by
peptide 93-112, which can also form aggregates owing to the
partial presence of the hydrophobic domain, provides further
evidence that the interaction blockade was not the result of
peptide aggregation.
Binding assays performed using four PrPC molecules
presenting small deletions on the putative Vn binding site,
revealed that the PrPC deletion mutants 105-112, 113-119,
Fig. 2. Mapping the binding sites within Vn and PrPC. (a) 125I-Vn was incubated over PrPC coated wells in the presence of PrPC peptides.
Binding to PrPC was set as 100% and binding in the presence of peptides was expressed as a percentage thereof. PrPC peptides 103-122 and
113-132 interfered with binding to Vn (*P<0.01, Student’s t-test). (b) 125I-Vn binding to deletion mutant proteins 105-112, 113-119, or
105-128 His6-PrPC was markedly reduced relative to binding to wild-type PrPC, which was set as 100% (*P<0.01, Student’s t-test). 51-90
and 120-125 His6-PrPC proteins exhibited 125I-Vn binding that did not differ significantly from the wild-type protein. (c,d) The hydropathy
plots compare the mouse PrPC amino acid sequence from a.a. 104 to 127 and human Vn peptides with complementary hydropathy pattern: (c)
Vn262-275 and (d) Vn309-322. (e) 125I-Vn was incubated in PrPC-coated wells in the presence or absence of the indicated concentrations of Vn
peptides and radioactivity levels were determined. 125I-Vn binding was disrupted in the presence of Vn309-322Hu and Vn307-320Mo (*P<0.01 vs
binding to PrPC alone, Student’s t-test) at the two higher concentrations tested. (f) Binding of peptide Vn307-320Mo to immobilized PrPC. Wells
were coated with wild-type, 105-119, 113-119 or 105-128 His6-PrPC proteins and incubated with 1 M 125I-Vn307-320Mo. 125I-Vn307-320Mo
binding to immobilized PrPC was reduced in 105-128, 105-119 or 113-119 His6-PrPC proteins relative to wild-type PrPC controls
(*P<0.001, Tukey’s test). Inset shows an overlay assay, where His6-PrPC or PrPc peptides 43-62 and 103-122 spotted into a membrane were
incubated with biotin labeled Vn307-320Mo followed by streptavidin-HRP.
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and 105-128 did not bind Vn, whereas mutants 51-90 and
120-125 exhibited binding capacity similar to that of the
wild-type molecule (Fig. 2b). These data corroborate that the
region comprising a.a. 105-119 of PrPC includes the binding
site for Vn. As this domain is inserted into the N-terminal
random coil of the PrPC molecule (Riek et al., 1996), these
deletions are not expected to disturb PrPC secondary or tertiary
structure. Since all the experiments herein were conducted with
E. coli recombinant His6-PrPC, we were unable to evaluate
possible roles of PrPC sugar residues in this interaction.
However, as the binding site was mapped to a region lying
outside the glycosylation site, it is unlikely that sugar residues
on PrPC are essential for its interaction with Vn.
In accordance with the complementary hydropathy theory
(Brentani, 1988), which states that peptides presenting
opposite hydropathy profiles can bind one another, we used
HYDROLOG software to search for Vn sequences whose
hydropathy profile was more than 70% complementary to the
PrPC 105-119 peptide. Two human Vn domains presented this
profile, one from residues 262-275 (Fig. 2c) and another from
residues 309-322 (Fig. 2d). We performed competition assays
using both peptides and, as controls, two peptides randomly
chosen from within the Vn sequence (Vn161-174 and Vn289-302)
along with a peptide containing the RGD sequence (VnRGD)
(Ruoslahti and Pierschbacher, 1987). The peptides Vn309-322Hu
(human Vn) and Vn307-320Mo (the equivalent peptide for mouse
Vn) competed for PrPC-Vn interaction, thus identifying this
domain as the putative binding site for PrPC (Fig. 2e).
We also performed binding assays using the 125I-Vn307-320Mo
peptide and wild-type His6-PrPC or PrPC deletion mutants
105-128, 105-119 and 113-119. Vn307-320Mo peptide
readily bound wild-type PrPC, whereas very low binding was
observed with all of the deletion mutants (Fig. 2f). Using
overlay assays we demonstrated that peptide Vn307-320Mo
directly binds the PrPC peptide corresponding to a.a. 103-122,
but not to a.a. 43-62 (Fig. 2f inset). These data are consistent
with the presence of an interaction between the PrPC domain
105-119 and the Vn domain 307-320 (mouse Vn).
Supplementary material Fig. S2a shows a schematic
representation of PrPC and Vn, along with their main ligands
and respective binding sites (Lee et al., 2003; Schvartz et al.,
1999). Although there is moderate sequence diversity in Vn
across species, the PrPC binding domain is generally well-
conserved (see supplementary material Fig. S3a). Chicken Vn,
which has the greatest divergence relative to human Vn, bound
PrPC in the same manner as human Vn (see supplementary
material Fig. S3b). Furthermore, peptides from the PrPC-
binding domain derived from chicken and mouse Vn sequences
were also able to inhibit the PrPC interaction with human Vn
(see supplementary material Fig. S3c), suggesting that the
PrPC-Vn interaction is evolutionarily conserved.
PrPC and Vn expression in DRG from embryonic mice
Since Vn and PrPC have been detected early in development
(Miele et al., 2003; Seiffert et al., 1995), we performed
immunohistochemistry assays in E12.5 mice embryos.
Journal of Cell Science 120 (11)
Fig. 3. PrPC and Vn expression in mouse embryos. E12.5 Prnp+/+ sagittal (a-f) or coronal (g-l) sections reacted with anti-PrPC mouse serum
(a,b,c,g,h,i), rabbit serum anti-Vn (d,e,f,j,k,l) or non-immune mouse or rabbit serum (insets in panels a and j, respectively). E12.5 ZrchI Prnp0/0
mouse sagittal sections reacted with anti-PrPC mouse serum (m and n) or anti-Vn serum (panel o). Br, brain; Ht, heart; Lu, lung; Sp, spinal
cord; Ga, dorsal root ganglia.
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1919PrPC-vitronectin induces axonal growth
Immunohistochemistry assays were performed in ZrchI
Prnp+/+ (Fig. 3a-l) and ZrchI Prnp0/0 (Fig. 3m-o) E12.5 mice
embryos using anti-PrPC (Fig. 3a-c,g-i,m,n) and anti-Vn
antibodies (Fig. 3d-f,j-l,o) in sagittal sections (Fig. 3a-f,m-o)
and coronal sections (Fig. 3g-l). The antibodies used have been
extensively tested in western blotting assays, and show
specificity for PrPC (Zanata et al., 2002b) or Vn (data not
shown). Control experiments with mouse or rabbit serum
produced no immunolabeling (Fig. 3 insets in a and j,
respectively).
In accordance with previous data (Miele et al., 2003), we
observed strong PrPC immunoreactivity in the developing
brain, spinal cord (Fig. 3g) and DRG (Fig. 3a,g). In DRG,
although axons and forming axonal fibers were heavily labeled,
nuclei were not labeled and neuronal bodies showed only weak
labeling (Fig. 3b,c,h,i). PrPC expression could be detected only
at E10, in the nervous system and in the heart (data not shown).
As development proceeds, those organs still show high levels
of immunoreactivity. Immunolabeling in other organs such as
kidney, lungs and muscles could only be seen later (E18) in
development (data not shown). Sections from Prnp0/0 mouse
embryos did not bind the anti-PrPC antibody, proving the
specificity of the immunohistochemistry reaction (Fig. 3m,n).
Vn immunolabeling was more intense than PrPC,
but presented a similar pattern in brain, spinal cord
(Fig. 3j) and DRG (Fig. 3d,j). In the DRGs,
expression was predominantly observed in growing
axons and nerves (Fig. 3e,f,k,l). Vn starts to be
expressed at E8, through the whole embryo.
Similarly to PrPC, at E10 it presents high expression
in the heart and nervous system. As development
proceeds, those organs still present high levels of
immunoreactivity, whereas immunolabeling can
also be seen in other organs such as kidney, lung and
muscles. Expression in the liver is very abundant
(data not shown), since this organ secretes Vn to the
blood. In PrPC-null mice, the pattern of Vn
expression in DRG (Fig. 3o) as well as in other
tissues (data not shown) was the same as that in
wild-type mice. Immunofluorescent confocal
images confirmed that PrPC and Vn strongly co-
localized in DRG cells (Fig. 4a,b) and in growing
nerves (Fig. 4c).
Vn binds PrPC in vivo
To verify whether Vn could bind PrPC in the cell
surface, we labeled Vn with Alexa Fluor 568 (see
supplementary material Fig. S1b). Dissociated DRG
cells were treated with Alexa 568-Vn and subjected
to PrPC fluorescent immunocytochemistry (Fig. 5a
upper panel). We observed the co-localization of Vn
and PrPC at the cell surface. Images of live SN-56
cells (Blusztajn et al., 1992; Hammond et al., 1990)
transfected with green fluorescent protein (GFP)-
PrPC and treated with Alexa 568-Vn showed co-
localization of PrPC with Vn at the cell surface (Fig.
5a bottom panel).
SDS-PAGE of GFP-PrPC-transfected HEK293
cell proteins eluted from a pull-down assay using
purified Vn covalently coupled to CNBr-Sepharose
followed by immunoblotting, revealed a band of ~60
kDa [the expected molecular mass for GFP-PrPC (Lee et al.,
2001)] when anti-GFP (lane 3) or anti-PrPC antibodies (lane 6)
were applied (Fig. 5b). When the same procedure was
conducted with extracts from non-transfected cells (lanes 1 and
4) or with those from cells transfected with GFP alone (lanes
2 and 5) no binding to the Vn-Sepharose was observed. These
results indicate that PrPC, but not GFP alone, binds to Vn. The
levels of endogenous PrPC in HEK293 cells were too low for
their association with Vn to be detected.
PrPC-Vn interaction mediates DRG axonal growth
We investigated the possible role in axonal growth of the
interaction between PrPC and Vn, which are expressed in
elongating DRG and medulla axons and are implicated in
neuronal differentiation (Graner et al., 2000a; Graner et al.,
2000b; Martinez-Morales et al., 1995; Martinez-Morales et al.,
1997; Pons et al., 2001; Sales et al., 2002). Cultured DRG
explants from E12.5 mice expressing PrPC (ZrchI Prnp+/+)
(Fig. 6a inset) in the presence of Vn for 36 hours produced
axonal growth (Fig. 6a). Vn peptide, Vn307-320Mo,
corresponding to the PrPC-binding site of the mouse Vn
molecule elicited the same effect as that triggered by the whole
molecule (Fig. 6b), whereas Vn peptide Vn161-174 (Fig. 6d) had
Fig. 4. PrPC and Vn colocalize in embryonic DRG. Confocal microscopy images
of E12.5 mouse sagittal sections reacted with anti-Vn rabbit serum (green) and
anti-PrPC mouse serum (red). Superimposed red and green images are shown in
the merge column. The top row of images (a) shows three ganglia in a low
magnification (as indicated by the dotted lines); the middle row of images (b)
shows a single ganglion in a higher magnification; and the bottom row (c) shows
a growing nerve region.
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no effect, even at concentrations 20-fold higher than peptide
Vn307-320Mo.
ZrchI Prnp0/0 mouse (Bueler et al., 1992) DRG neurons
cultured on Vn presented neurite growth rates (Fig. 6g) similar
to that of wild-type DRG neurons (Fig. 6a). Nevertheless, in
opposition to what has been demonstrated for wild-type DRG,
Vn peptide Vn307-320Mo (Fig. 6f), which mimics the PrPC
binding site, was unable to induce axon growth in Prnp0/0 DRG
neurons. Vn peptide Vn161-174 also had no effect on Prnp0/0
DRG neurons (Fig. 6e). Treatment of Vn-stimulated DRG with
rabbit anti-PrPC antibody blocked axonal growth in cultures
from wild-type animals but not in those from PrPC-null mice
(Fig. 6h). Data representing the average axon length from each
treatment are summarized in Fig. 6h.
To rule out the possibility of spurious results because of
genetic background, we conducted our key experiments in both
ZrchI (Bueler et al., 1992) and Npu (Manson et al., 1994) PrPC-
null mice. DRG from Npu Prnp–/– mice and their wild-type
controls plated for 24 hours in the presence of Vn presented
similar axonal growth (Fig. 6i). On the other hand, when plated
with Vn307-320Mo, only Npu Prnp+/+ DRG grew axons and no
effect was observed with either knockout or wild-type cells
when an irrelevant Vn peptide (Vn161-174) was used (Fig. 6i).
Inclusion of an antibody against PrPC peptide 106-126
(Chiarini et al., 2002) (Fig. 6i) completely blocked axonal
growth in cultures from wild-type animals, whereas non-
immune purified IgG had no effect (Fig. 6i). We also carried
out dissociated DRG cell cultures in the presence of Vn to
measure the percentage of cells with neurites, and observed
that the positive responsiveness to Vn was the same for ZrchI
Prnp+/+ and Prnp0/0 neurons (Fig. 6j).
The experiments using anti-PrPC antibodies or the Vn307-320
peptide demonstrated that axonal growth can be supported
specifically by the PrPC-Vn interaction. Nonetheless, the whole
Vn molecule induces the same axonal outgrowth pattern in
wild-type and PrPC-null neurons. The similarity between the
effect of Vn in wild-type and PrPC-null DRG suggests that
there may be another Vn receptor that can compensate for the
PrPC deficiency.
In fact, flow cytometry analysis shows that Alexa 568-Vn is
able to bind equally to the surface of PrPC-null and wild-type
cells (see supplementary material Fig. S4a). Indicating that in
the absence of PrPC other Vn receptors are present at the cell
surface.
Integrin participation in Vn-induced axonal growth is
enhanced in the absence of PrPC
The obvious targets for the putative compensatory mechanism
suggested by the above data are integrins, the classical Vn
receptors that interact with this molecule through the Vn-RGD
peptide. We performed functional assays using the RGD
peptide, which has an advantage over antibodies in that it can
simultaneously trigger or halt several integrin dimers (Isahara
and Yamamoto, 1995; Monier-Gavelle and Duband, 1997).
The RGD peptide can be used for inhibition or stimulation of
the neuritogenesis depending on its presentation. In solution,
the RGD peptide does not support cell adhesion and thus can
be used to perform competition assays (Pierschbacher and
Ruoslahti, 1987). Conversely, when coupled to BSA, the
peptide adheres to the coverslip and supports cell adhesion
(Danilov and Juliano, 1989).
As shown in Fig. 7a, the VnRGD peptide at a concentration
of 8 M inhibited Vn-stimulated axonal growth of ZrchI
Prnp0/0 DRG neurons. The impairment reached poly-L-lysine
growth levels (about 50% of that observed in Vn). Vn-
stimulated axonal growth in Prnp+/+ neurons was impaired
only when the VnRGD peptide reached a concentration of 12
M. Additionally, we measured the axonal growth induced by
VnRGD-BSA and observed that ZrchI Prnp0/0 DRG are more
responsive than Prnp+/+ DRG (Fig. 7b). Prnp0/0 DRG neurons
extended axons in 0.5 nmol of adsorbed peptide, whereas
Prnp+/+ DRG neurons did not exhibit any axonal growth, even
in the presence of a 20-fold higher concentration of the peptide.
Thus, Prnp0/0 DRG cells were more responsive than the
Prnp+/+ cells to the RGD peptide. To further confirm these
results, we plated Npu Prnp–/– and Prnp+/+ DRG over adsorbed
RGD-BSA. We observed that Npu Prnp–/– DRG neurons were
also more responsive to RGD-BSA than Npu Prnp+/+ DRG
neurons (Fig. 7c). Thus, we can be confident that the above
Journal of Cell Science 120 (11)
Fig. 5. Vn binds PrPC in vivo. (a) Confocal images of dissociated
DRG cells treated with Alexa 568-Vn (red) and immunolabeled with
anti-PrPC (green) are shown in the top row. Confocal images of SN56
cells transfected with GFP-PrPC (green) and treated with Alexa 568-
Vn (red) are shown in the bottom row. (b) Pull down assay from cell
extracts incubated with Vn-Sepharose. Western blots of Vn-
Sepharose-bound proteins from untransfected (lanes 1 and 4), GFP
transfected (lanes 2 and 5) or GFP-PrPC transfected (lanes 3 and 6)
HEK293 cells. Blots immunolabeled with anti-GFP (lanes 1 to 3) or
anti-PrPC (lanes 4 to 6) antibodies revealed that PrPC, but not GFP
alone, binds to Vn.
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findings were not due to any spurious effect present only in
ZrchI animals. These data demonstrate that PrPC-ablated DRG
neurons have a greater dependence upon integrins for axonal
outgrowth than do their respective wild-type cells.
To test whether the activation state of Vn-binding integrins
was altered, we measured the level of active v3 integrin
in adhering ZrchI Prnp0/0 DRG cells through an
immunofluorescence assay with the ligand-mimetic antibody
WOW-1 (Pampori et al., 1999). ZrchI Prnp0/0 DRG neurons
showed a 30% higher level of v3 activation than Prnp+/+
DRG neurons (Fig. 7d). We tested whether Npu Prnp–/–
neurons presented a similar increase in integrin activity using
the commercially available anti-ligand-induced binding sites
(LIBS) antibody AP5 (Faccio et al., 2002). Dissociated Npu
Prnp–/– DRG neurons showed greater 3 activity than Prnp+/+
cells (Fig. 7e). Accordingly, ZrchI Prnp0/0 primary mouse
embryonic fibroblasts (PMEFs) also showed 30% more
integrin v subunit expression than wild-type PMEFs (see
supplementary material Fig. S4b). Together, these findings
indicate that a higher integrin activity, particularly that from
v3 integrin, is present in DRG after ablation of PrPC.
Discussion
In the past few years, many PrPC-binding proteins have been
identified. Among these the ECM protein Ln (Graner et al.,
2000a; Graner et al., 2000b) and glycosaminoglycans
(Gonzalez-Iglesias et al., 2002) have been of particular interest.
These previous findings suggested that PrPC might act as a
wide-range cell surface receptor, capable of binding numerous
ECM proteins. However, the present findings indicate that PrPC
interaction with ECM proteins is not a broad-spectrum
phenomenon, but rather that PrPC specifically binds Vn with
high affinity, and does not readily bind Fn or type IV collagen.
We proposed that PrPC participates in a multi-protein
complex, the biological effects of which would be dependent
both on the affinity and accessibility of each member of the
complex (Martins and Brentani, 2002). The present
competition experiments demonstrated that PrPC-Vn
interaction in vitro has a higher affinity, Kd 10–8 M, than that
between PrPC and STI1, Kd 10–7 M (Zanata et al., 2002b).
Furthermore, the Vn binding domain in PrPC in residues 105-
119 (Fig. 2a) overlaps with the STI1-binding domain (Zanata
et al., 2002b), indicating that PrPC interactions with Vn or STI1
are mutually exclusive, with the first being more favorable and
conditioning the latter to local protein availability and levels.
The ability of PrPC-STI1 to provide neuroprotection against
programmed cell death (Chiarini et al., 2002) and
neuritogenesis in hippocampal neurons (Lopes et al., 2005),
whereas PrPC-Vn engagement promotes axonal growth in
DRG, provide prime examples of how cell fate can be directly
influenced by the molecular environment of the cell.
PrPC domain 105-128, which contains the Vn and STI1
binding sites, is highly conserved across species (Gabriel et al.,
1992), and is indeed identical in mice and humans. This
domain also includes proteolytic sites (Jimenez-Huete et al.,
1998) and hereditary prion disease-associated mutations
(Mastrianni and Roos, 2000), indicating that this region and
probably its interaction with Vn and STI1 have an important
role in vivo. For example, it was recently reported that this
domain is linked to the toxicity of PrPC accumulated in the
cytosol through binding to Bcl-2 (Rambold et al., 2006).
Although PrPC-Ln and PrPC-Vn interactions present a
similar Kd, (Graner et al., 2000a), we demonstrated that lower
concentrations of Vn than Ln are needed to disrupt the PrPC-
Vn interaction. Since the Ln-binding site is located in residues
173-183 of PrPC (Coitinho et al., 2006), the Ln 1 peptide (the
Fig. 6. PrPC-Vn interaction supports axonal
growth in DRG from E12.5 mouse embryos.
ZrchI Prnp+/+ (a-d) and ZrchI Prnp0/0 (e-g)
DRG were cultured on poly-L-lysine-coated
coverslips (c), 200 nM Vn (a and g), 0.4 M
peptide Vn307-320Mo (b and f), 0.4 M peptide
Vn161-174 (d and e) and Vn plus anti-
recombinant PrPC antibody 13 g/ml or Vn
plus irrelevant IgG 13 g/ml (h). Inset dark-
field image in a shows a DRG subjected to
anti-PrPC immunohistochemistry.
(h) Comparison of mean axonal growth per
DRG from ZrchI Prnp+/+ (white bars) and
Prnp0/0 mice (grey bars) for the conditions
described above. *P<0.001 vs Pll control,
Tukey’s Test. (i) Comparison of mean axonal
growth per DRG of at least 12 ganglia from
Npu Prnp+/+ (striped bars) and Prnp–/– mice
(black bars) for each of the following
conditions: Pll, 200 nM Vn, 0.2 or 0.4 M
Vn307-320Mo, 0.4 M Vn161-174, Vn plus
irrelevant IgG or 0.6 g/ml anti-PrPC peptide
106-126. *P<0.001 vs Pll control, Tukey’s
Test. (j) The percentage of cells from ZrchI
Prnp+/+ (white bars) and ZrchI Prnp0/0 (grey
bars) dissociated DRG neurons that grow
axons increased with increasing concentrations
of Vn; *P<0.001 vs Pll control, Tukey’s test.
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PrPC-binding site in Ln) does not disrupt the PrPC-Vn complex
(Fig. 1d). Thus, it is plausible that in vitro, the Ln molecule
may interact with PrPC, and thereby disturb PrPC-Vn binding
by steric hindrance. On the other hand, steric hindrance may
not occur in vivo because of the ECM organization or to the
presence of biologically active proteolytic fragments from the
Ln molecule (Chen, Z. et al., 2003). Indeed, the signals
triggered by each of these PrPC ligands may have cooperative
roles in some biological events. In developing cerebellar
granule cells, the presence of Ln induces proliferation, whereas
during migration these cells find Vn and differentiate (Pons et
al., 2001). Therefore, we believe that PrPC has pleiotropic
functions that depend upon its cellular expression as well as
the greater contextual cellular milieu.
We exploited the complementary hydropathy principle
(Brentani, 1988) to map a.a. 309-322 as the PrPC-binding site
in the human Vn molecule. To date, more than 40 protein-
protein interactions have been shown to comply with this
principle (Heal et al., 2002), including a Vn and fibrinogen
interaction with the integrin IIb3 (Gartner et al., 1991) and
the PrPC-STI1 interaction (Martins et al., 1997; Zanata et al.,
2002b). This region (residues 309-322) of human Vn has never
been shown to bind other proteins (Schvartz et al., 1999).
According to the three-dimensional theoretical model of Vn
(Xu et al., 2001), this mainly hydrophobic peptide is partially
buried. Conversely, it should be considered that the threading
algorithm (Xu and Xu, 2000) used to create this model makes
use of an energy function that penalizes the exposure of
hydrophobic side chains, whereas it is known that protein-
binding sites are generally hydrophobic (Tsai et al., 1997).
Since it was not considered that this particular region could be
a binding site, protein interactions were not taken into
consideration in these calculations (Xu et al., 2001).
Vn is composed of multiple domains known to bind distinct
proteins (see supplementary material Fig. S2a). The first 44
amino acids comprise a somatomedin-like domain, which
harbors plasminogen activator inhibitor-1. This somatomedin-
like domain is followed by the RGD peptide domain (residues
53-64), which is responsible for integrin binding, and an acidic
stretch involved in binding of the thrombin-antithrombin III
complex. Two binding sites for collagen have been described,
one adjacent to the RGD site and other adjacent to the heparin-
binding site. The Vn is composed of six hemopexin domains
(a.a. 132-459). The C-terminal part of the molecule harbors a
plasminogen (a.a. 332-348), a heparin (a.a. 348-346) and a
glycosaminoglycan-binding site (a.a. 348-361). A subregion of
this domain (a.a. 348-370) has also been implicated in
plasminogen activator inhibitor-1 binding (Preissner, 1991;
Schvartz et al., 1999). Thus although the PrPC-binding site in
Vn has not been assigned to bind other proteins, it is close to
the heparin-binding domain. Heparin is efficient in competing
PrPC-Vn interaction (see supplementary material Fig. S2a),
since it is able to bind both PrPC (Pan et al., 2002) and Vn
(Francois et al., 1999). Thus, as proposed above, PrPC
pleiotropic functions are dependent on the greater contextual
cellular milieu.
There are many Vn receptors found on the cell surface, such
as integrins IIb3, v1, v3 and v5 (Felding-
Habermann and Cheresh, 1993). Each one of these binds to the
Vn RGD domain with a different affinity and induces specific
signals within cells (Takagi et al., 2002). Our demonstration
herein that RGD peptide did not compete for the PrPC-Vn
Journal of Cell Science 120 (11)
Fig. 7. Integrins compensate for the absence of PrPC to support Vn-
induced axonal growth. (a) VnRGD peptide abrogates Vn-induced
axonal growth in cultured ZrchI Prnp0/0 (grey bars) DRGs at lower
concentrations (8 M) than that (12 M) necessary for the same
effect in Prnp+/+ (white bars) DRGs. Treatment with the irrelevant
peptide Vn161-174 (12 M) had no effect. *P<0.001 vs poly-L-lysine
(Pll) Tukey’s test. (b) Exposure to adsorbed VnRGD-BSA peptide
(0.5, 5, 1 or 10 nmol) increased axonal growth in DRG cells from
ZrchI Prnp0/0 mice, but not from ZrchI Prnp+/+ mice. *P<0.001 vs
Pll control, Tukey’s test. (c) Adsorbed VnRGD-BSA peptide (1 nmol)
induced axonal growth in cultured DRG cells from Npu Prnp–/– mice
(black bars) whereas no axonal growth was present at this
concentration of absorbed VnRGD-BSA peptide in Npu Prnp+/+ cells
(striped bars). *P<0.001 vs Pll control, Tukey’s test. (d) ZrchI
Prnp0/0 dissociated DRG cells exhibited greater WOW-1
immunoreactivity than those from ZrchI Prnp+/+ mice, indicating that
the knockouts had greater levels of activated v3 integrin. *P<0.001
vs Prnp+/+, Mann-Whitney’s test. (e) Npu Prnp–/– dissociated DRG
cells exhibited greater AP5 immunoreactivity than Npu Prnp+/+,
indicating that the knockouts had greater levels of activated 3
integrin. *P<0.001 vs Npu Prnp+/+, Mann-Whitney’s test.
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interaction indicates that Vn binds PrPC at a domain that is
distinct from the integrin-binding domain.
Since both PrPC and integrins participate in axonal growth,
it was surprising to observe a complete inhibition of Vn-
stimulated axonal growth in the presence of anti-PrPC antibody.
This finding suggests that PrPC occupies a part of the
macromolecular complex such that its inactivation by
antibodies may disturb the whole complex. The ability of Vn
peptide containing the PrPC-binding site to reproduce the
biological effects of the whole Vn in wild-type but not in PrPC-
null DRG, further suggests that PrPC is an exclusive ligand for
the Vn 307-320 domain. The fact that Vn307-320Mo (Fig. 7) and
VnRGD (Danilov and Juliano, 1989) are both able to substitute
for the whole Vn molecule in the axonal growth phenomenon
is consistent with the hypothesis that PrPC and integrins act
through the same signal transduction pathway. Notably, the
data showing that VnRGD is able to inhibit axonal growth in
wild-type neurons highlights the importance of the integrins in
this process.
In spite of the important functions for PrPC described over
the past few years (Chiarini et al., 2002; Lopes et al., 2005;
Mouillet-Richard et al., 2000; Rambold et al., 2006; Steele et
al., 2006), PrPC-null mice have only minor defects (Bueler et
al., 1992). One explanation for this near-normal phenotype is
that PrPC ablation may be compensated by proteins with
redundant functions (Bueler et al., 1992). This seems to be the
case here, because the whole Vn molecule induced DRG
axonal growth in both wild-type and PrPC-null neurons. On the
other hand, PrPC-null (both ZrchI and Npu) DRG axonal
growth is more sensitive to RGD than the wild-type, indicating
that the cellular signaling involved in this phenomenon is more
dependent upon integrins in neurons from the knockout
animals. Additionally, we observed 30% more activated v3
in DRG from PrPC-null mice than in their wild-type
counterparts. This increase in activated integrins may represent
a compensatory mechanism developed by the PrPC-null
animals, where the use of proteins already involved in this
specific phenotype can prevent malformation of the nervous
system.
Numerous examples of compensatory mechanisms have
been reported (Kitami and Nadeau, 2002; Schwarz et al., 2002)
and promiscuous cell signaling transduction pathways are
targets for molecular redundancy (Xian et al., 2001). Indeed,
PrPC-null mice have been reported to have hyper-activation of
extracellular signal-related kinase (ERK) (Chiarini et al., 2002;
Lopes et al., 2005; Brown et al., 2002). PrPC (Zanata et al.,
2002b) and integrins (Roberts et al., 2003) are upstream
MAPK effectors, which means that at least in this situation, an
integrin could substitute for PrPC signaling.
GPI-anchored proteins, such as PrPC, can perform signaling
roles, integrating the ECM with the cytoskeleton. For example
the GPI-anchored raft-associated protein urokinase type
plasminogen activator receptor (uPAR) performs complex
signaling involved in cell adhesion, proliferation and migration
in response to several ligands including Vn (Blasi and
Carmeliet, 2002). To modulate internal cell signaling, GPI-
anchored proteins must interact with transmembrane adaptors,
such as integrins, G-protein-coupled receptors and caveolins
(Blasi and Carmeliet, 2002). Despite the involvement of uPAR
in cell signaling and diverse biological functions, uPAR-null
mice have an apparently normal phenotype (Bugge et al.,
1995). Thus, a GPI-anchored protein can be associated with
critical regulatory cell tasks and the lack of a severe phenotype
in knockout mice cannot demonstrate that the protein is not
normally involved in important phenotypes.
In summary, the characterization of PrPC as a ligand for Vn
and its involvement in axonal growth allowed us to
demonstrate the relevance of PrPC in the development of the
peripheral nervous system (PNS). Additionally, compensatory
mechanisms occurring during embryogenesis are turned on
when PrPC is ablated. Thus, at least for this event, our findings
indicate that redundancy for PrPC interactions resides within
the integrin pathway. The importance of PrPC in the PNS has
been increasingly recognized because PNS is a target for PrPC
conversion to PrPSc, and thus is critically involved in the prion
neuroinvasion (Glatzel et al., 2004). Providing further support
for PNS involvement in prion neuroinvasion, are the
observations that PrPC is retrogradely transported in peripheral
nerves (Moya et al., 2004) and that prion accumulation occurs
in DRG and in autonomic ganglia isolated from patients with
Creutzfeldt-Jakob and Gerstmann-Sträussler-Scheinker (Haik
et al., 2003; Ishida et al., 2005; Lee et al., 2005). The present
findings together with these previous observations indicate that
the physiological functions of PrPC in peripheral nerves
warrant further investigation.
Materials and Methods
Proteins
Vn and Fn were purified from human plasma (Engvall and Ruoslahti, 1977; Yatohgo
et al., 1988) and mouse His6-PrPC was cloned (Zahn et al., 1997) and expressed
(Zanata et al., 2002b). Type IV collagen and albumin are from Sigma. Four PrPC
deletion mutants were constructed using wild-type cDNA by sequential PCR
amplification (Ausubel et al., 1993); cloned into pRSET A vector (Invitrogen) and
expressed and purified as the wild-type His6-PrPC. Mutant His6-PrPC molecules are
soluble, sensitive to proteinase K and posses nearly the same -helix and -sheet
content as the wild-type protein. The following internal primers were used for
sequential PCR amplification: 51-900R-TACCCCCTCCTGGGTAACG GTTG -
CCTCC; F-GAGGGATCCAAAAAGCGGCCAAAG; 105-112R-CCAG CTGC -
CGCAGCCCCTGGTTGGCTGG; F-CCCAGCAAACCAGGGGCTGCG GCAGC -
TGG; 113-119R-CCCCATTACTGCCACATGCTTGAGGTTG; F-AAGCATGT -
GGCAGTAGTGGGGGGCCTT; 120-125R-CAGCATGTAGC CTGC CCCAGC -
TGCCGC; F-GCAGCTGGGGCAGGCTACATGCGGGAGC; 105-128F-GGAA -
C AAGCCCAGCAAACCACTGGGGAGCGCCATGACGG; R-GTCCATGGCGC -
TCCCCAGTGGTTTGCTGGGCTTTGTTCC. The following external primers were
used for all mutants: F-AGAGA ATTC TCAGCTGGATCTTCTCCCGTC; R-GAG -
GGATCCAAAAAGCGGCCAAAG.
Peptides
Twenty peptides covering the whole mouse PrPC (23-231) (Zanata et al., 2002b)
were used. STI1 peptide (230-ELGNDAYKKKDFDKAL-245) (Zanata et al.,
2002b), laminin -1 peptide (1575-RNIAEIIKDI-1584) (Graner et al., 2000a) and
six Vn peptides: VnRGD KPQVTRGDVFTMPE; Vn161-174 AEEELCSGKPFDAF;
Vn262-275 AHSYSGRERVYFFK; Vn289-302 SQEECEGSSLSAVF; Vn309-322Hu
QRDSWEDIFELLFW and Vn307-320Mo QRDSWENIFELLFW were synthesized by
Neosystem (Strasbourg, France). The subscript numbers indicate amino acid
position in the Vn molecule; the first five peptides follow the human (Hu) Vn
sequence and the last one follows the mouse (Mo) Vn sequence.
Antibodies
Anti-PrPC used for western blotting, immunohistochemistry and immuno -
fluorescence reactions is a polyclonal antibody obtained by His6-PrPC immunization
in PrPC-null mice. Rabbit polyclonal antibodies obtained by His6-PrPC (Bethyl) or
PrPC peptide 106-126 (Neosystem) immunization were used in DRG axon growth
assays (Chiarini et al., 2002; Zanata et al., 2002b). 
The WOW-1 antibody, kindly provided by Prof. Sanford Shattil (University of
California), recognizes the active form of v3; the heavy chain hypervariable
region of an antibody against activated IIb3 was replaced with a single v
integrin-binding domain (from an adenovirus RGD-rich protein involved in its
internalization mediated by v) (Felding-Habermann et al., 2001; Pampori et al.,
1999). The AP5 antibody (GTI Diagnostics) is an anti-LIBS antibody that
recognizes the 3 N-terminus and is regulated by cation binding at a site distinct
from the LIBS (Honda et al., 1995). At normal extracellular Ca2+ levels, AP5 binds
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to 3 only when the integrin is in the ‘activated’ conformation (Faccio et al., 2002).
Anti-GFP was from Becton Dickinson and anti-Vn was obtained by rabbit
immunization with purified Vn.
Overlay assay
The indicated amounts of Ln, Fn, Vn, type IV collagen and BSA were adsorbed
onto nitrocellulose membranes. Blocking was performed in 5% milk in TBST (TBS
0.05% pH 7.4 Tween-20) for 2 hours at room temperature and membranes were
then washed. His6-PrPC (7 g) was labeled with 0.5 mCi Na125I (Amersham
Biosciences) using one iodobead (Pierce). The labeled protein was incubated with
the membrane for 16 hours at 4oC. After washing, an X-ray film (Hyperfilm,
Amersham Biosciences) was exposed to the membrane.
3 g His6-PrPC or PrPC peptides 43-62 or 103-122 was adsorbed onto
nitrocellulose membranes. After blocking, Vn307-320Mo was labeled with biotin using
an EZ-Link Sulfo-NHS-LC-Biotinylation Kit (Pierce) and incubated with the
membrane for 16 hours at 4°C, followed by Streptavidin-HRP (Sigma) for 1 hour
at room temperature.
Binding assays
Binding experiments were conducted as previously described (Graner et al., 2000a;
Martins et al., 1997). Briefly, His6-PrPC or His6-PrPC deletion mutants (2 g) were
adsorbed in polystyrene wells and blocked with 2% BSA. Wells were incubated for
3 hours at 37°C with Na125I-labeled Vn or Vn307-320Mo coupled to BSA. The wells
were washed, and radioactivity was measured in a gamma counter (Mini gamma
counter, LKB-Wallac). Data were analyzed using the Scatchard Method (Scatchard,
1949).
Competition assays
Unlabeled PrPC peptides (32 M) were pre-incubated with 38 nM of 125I-Vn for 2
hours at room temperature. Peptides and 125I-Vn were added to the His6-PrPC coated
wells and incubated for 3 hours at 37°C. The wells were washed and the
radioactivity was measured. Vn, STI1, Ln whole proteins or STI1 and Ln peptides
were pre-incubated with coated His6-PrPC for 2 hours at room temperature followed
by 3 hours at 37°C with 125I-Vn. After washing, the radioactivity was measured.
Cell transfection and pull-down assay
HEK293 cells were transfected with pEGFP-C1 (Clontech) or pEGFP-STI1 (Zanata
et al., 2002b) by calcium phosphate co-precipitation as previously described (Puchel
et al., 1995). After 48 hours in culture, transfected cells were lysed in NP40 (0.5%
in PBS). Cell extracts were pre-cleared by treatment with 30 l of inactive CNBr-
Sepharose (reactive groups previously blocked) for 1 hour at 4°C.
Vn was covalently coupled to CNBr-Sepharose 4B (Amersham) according to the
manufacturer’s instructions, and 30 l Vn-CNBr-Sepharose was incubated in pre-
cleared cell extracts for 16 hours at 4°C. After washing with 0.5% NP-40 in PBS,
bound proteins were eluted with Laemmli buffer and analyzed by western blotting
using mouse anti-PrPC (1:1000) or anti-GFP (1:3000) followed by anti-mouse HRP.
Alexa Fluor 568 Vn labeling and co-localization assay
Vn labeling was performed using an Alexa Fluor 568 labeling kit (Molecular
Probes). SN-56 cells, a mouse cholinergic septal neuronal cell line (Blusztajn et al.,
1992; Hammond et al., 1990), were transfected with GFP-PrPC using lipofectamine
(Invitrogen) as described previously (Lee et al., 2001). Transfected and
differentiated (1 mM cAMP for 1 day) SN-56 cells, were treated with 4 g Alexa
568-Vn for 1 hour at 4°C. After several washes with PBS, images of live cells were
acquired using a Bio-Rad Radiance 2100 laser-scanning confocal system coupled
to a Nikon microscope (TE2000-U). Dissociated DRG cells were incubated with 4
g labelled Vn for 1 hour at 4°C, fixed, submitted to immunofluorescence using
mouse anti-PrPC followed by anti-mouse Alexa Fluor 488, and images were
acquired as for SN-56 cells.
Animals
The ‘Principles of laboratory animal care’ (NIH publication 85-23, 1996) were
strictly followed in all experiments. ZrchI Prnp0/0 were provided by Dr Charles
Weissmann (Scripps Florida, FL) (Bueler et al., 1992). ZrchI Prnp+/+ mice were
generated by crossing F1 descendants from 129/SV and C57BL/6J matings. Npu
Prnp–/– (Manson et al., 1994) were provided by Bruce Chesebro and Richard Race
(Rocky Mountain Laboratories, National Institute of Allergy and Infectious
Diseases, MT). These animals were backcrossed to C57BL/10 mice for at least eight
generations. Heterozygous animals were mated and homozygous F1 descendants
from the same litter were crossed to generate Npu Prnp–/– or Npu Prnp+/+ embryos.
All of the adult animals used to generate Npu Prnp–/– and Npu Prnp+/+ embryos
were genotyped by PCR (Manson et al., 1994).
DRG explants
DRG from E12.5 mice (Bueler et al., 1992) were dissected and cultured in poly-L-
lysine coated glass coverslip in neurobasal medium (Invitrogen) with 2 mM
glutamine, 100 IU penicillin, 100 g/ml streptomicyn, B-27 (Invitrogen) and 50
ng/ml nerve growth factor (Sigma). In Fig. 7b,d, DRGs were plated in VnRGD-BSA
adsorbed coverslips. Treatments were performed immediately after plating and
ganglia were cultured for 24 (Fig. 6i,j, Fig. 7a-c) or 36 hours (Fig. 6a-h), fixed in
4% paraformaldehyde/0.12 M sucrose and stained with haematoxylin. The neurite
length was measured as the distance from the edge of the DRG to the tip of the
three longest neurites, and the mean value was used as the neurite length for each
DRG (Zanata et al., 2002a). At least 12 ganglia from three independent experiments
were considered for each individual data point. Cultures were dissociated by
enzymatic digestion of the dissected ganglia for 30 minutes with 1% trypsin in
neurobasal medium. After mechanical dissociation, 5104 cells per 13 mm2 well
were plated in the presence of Vn for 6 hours. Cells were fixed and stained as
described above and the percentage of cells presenting a neurite longer than one
cell body was calculated.
Immunohistochemistry
DRG explants grown in the presence of Vn were fixed and incubated for 4 hours
at 4°C with a mouse polyclonal antibody anti-PrPC, 1:250 (Chiarini et al., 2002)
followed by Alexa Fluor 568 anti-mouse IgG (Molecular Probes, Eugene, OR), for
40 minutes at room temperature. Ganglia were viewed with an Olympus IX70
microscope equipped with epifluorescence.
Formalin-fixed E12.5 mice embryos were embedded in paraffin and sections
submitted to immunohistochemistry as previously described (Lopes et al., 2005)
with mouse polyclonal anti-PrPC antibody (1:1000) (Chiarini et al., 2002) or with
rabbit polyclonal anti-Vn antibody (1:250).
Confocal immunofluorescence
E12.5 mouse embryos were immediately frozen and 3-m-thick cryostat sections
submitted to immunofluorescence as previously described (Lopes et al., 2005) with
a mouse polyclonal anti-PrPC antibody (1:250) (Chiarini et al., 2002) and rabbit
anti-Vn serum (1:100).
v3 activity assays
Dissociated DRG cells were plated on poly-L-lysine-coated coverslips and
incubated for 24 hours, fixed, and blocked as described above. Immunofluorescence
reaction with WOW-1 antibody (1:4) (Pampori et al., 1999) was undertaken for 16
hours at room temperature followed by Alexa Fluor 568 anti-mouse IgG (1:3000)
(Molecular Probes). Immunofluorescence with AP5 antibody (50 g/ml) was
performed in PBS with 3 mM Ca2+ for 16 hours at room temperature followed by
Alexa Fluor 568 anti-mouse IgG (1:3000). Images were acquired with an Olympus
IX70 microscope equipped with epifluorescence. To acquire the images, the digital
camera (Olympus DP70) exposure was set so that no fluorescence could be observed
in cells incubated with only secondary antibody. At least five fields of each coverslip
were imaged and the fluorescence of each cell was measured with the Image-Pro
Plus 4.1 (Media Cybernetics). At least 100 cells per coverslip were considered.
Statistical analysis
The mean values of at least three independent datasets are shown in the figures; the
error bars represent s.d. Fit to a normal distribution was evaluated with the
Kolmogorov-Smirnov test. The homogeneity of variances was assessed using
Levene’s test. The comparison of means for two independent samples was
performed using Student’s t-test or Mann-Whitney’s test. When comparing more
than two groups, an ANOVA or Kruskal Wallis test was used and a Tukey-HSD test
was used for multiple comparisons.
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